What users think about the differences between Caffeine and illicit/prescription stimulants for cognitive enhancement

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Franke, Andreas G ^a   Lieb, Klaus ^a   Hildt, Elisabeth ^b  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; CAFFEINE; CENTRAL STIMULANT AGENT; ILLICIT DRUG; METHYLPHENIDATE;

ADDICTION; ADULT; ARTICLE; COGNITION; COGNITIVE ENHANCEMENT; DECISION MAKING; DRUG USE; ETHICS; FEMALE; HUMAN; HUMAN EXPERIMENT; INTERVIEW; LEGAL ASPECT; MALE; MORALITY; NORMAL HUMAN; PERSONAL AUTONOMY; PERSONALITY; RISK FACTOR; STIMULUS RESPONSE; STUDENT ATTITUDE;

ADULT; BEHAVIOR; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; COGNITION; DECISION MAKING; DRUG USERS; FEMALE; HUMANS; MALE; NOOTROPIC AGENTS; PRESCRIPTION DRUGS; STREET DRUGS; STUDENTS; SUBSTANCE-RELATED DISORDERS;

EID: 84863094027     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040047     Document Type: Article

References (40)

1. Franke AG, Bonertz C, Christmann M, Huss M, Fellgiebel A, et al. (2011) Non-Medical Use of Prescription Stimulants and Illicit Use of Stimulants for Cognitive Enhancement in Pupils and Students in Germany. Pharmacopsychiatry 44: 60-66.
2. Franke AG, Lieb K, (2010) [Pharmacological neuroenhancement and brain doping: Chances and risks]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 53: 853-859.
3. Sahakian B, Morein-Zamir S, (2007) Professor's little helper. Nature 450: 1157-1159.
4. Farah MJ, Illes J, Cook-Deegan R, Gardner H, Kandel E, et al. (2004) Neurocognitive enhancement: what can we do and what should we do? Nat Rev Neurosci 5: 421-425.
5. Racine E, Forlini C, (2009) Expectations regarding cognitive enhancement create substantial challenges. J Med Ethics 35: 469-470.
6. Wilens TE, Adler LA, Adams J, Sgambati S, Rotrosen J, et al. (2008) Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry 47: 21-31.
7. Teter CJ, McCabe SE, Cranford JA, Boyd CJ, Guthrie SK, (2005) Prevalence and motives for illicit use of prescription stimulants in an undergraduate student sample. J Am Coll Health 53: 253-262.
8. Teter CJ, McCabe SE, LaGrange K, Cranford JA, Boyd CJ, (2006) Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration. Pharmacotherapy 26: 1501-1510.
9. Repantis D, Schlattmann P, Laisney O, Heuser I, (2010) Modafinil and methylphenidate for neuroenhancement in healthy individuals: A systematic review. Pharmacol Res 62: 187-206.
10. Smith ME, Farah MJ, (2011) Are prescription stimulants "smart pills"? The epidemiology and cognitive neuroscience of prescription stimulant use by normal healthy individuals. Psychol Bull 137: 717-741.
11. Maher B, (2008) Poll results: look who's doping. Nature 452: 674-675.
12. Schreiber GB, Maffeo CE, Robins M, Masters MN, Bond AP, (1988) Measurement of coffee and caffeine intake: implications for epidemiologic research. Prev Med 17: 280-294.
13. Franke AG, Christmann M, Bonertz C, Fellgiebel A, Huss M, et al. (2011) Use of coffee, caffeinated drinks and caffeine tablets for cognitive enhancement in pupils and students in Germany. Pharmacopsychiatry 44: 331-338.
14. Bublitz JC, Merkel R, (2009) Autonomy and authenticity of enhanced personality traits. Bioethics 23: 360-374.
15. Greely H, Sahakian B, Harris J, Kessler RC, Gazzaniga M, et al. (2008) Towards responsible use of cognitive-enhancing drugs by the healthy. Nature 456: 702-705.
16. Sententia W, (2004) Neuroethical considerations: cognitive liberty and converging technologies for improving human cognition. Ann N Y Acad Sci 1013: 221-228.
17. Metzinger T, Hildt E, (2011) Cognitive Enhancement. In: Illes J, Sahakian B, editors. pp. 245-264 editors. Oxford Handbook of Neuroethics. Oxford: Oxford University Press.
18. Kass LR, Blackburn EH, Dresser RS, Foster D, Fukuyama F, et al. (2003) President's Council on Bioethics. Beyond Therapy. Biotechnology and the Pursuit of Happiness, Washington.
19. Racine E, Forlini C, (2010) Cognitive Enhancement, Lifestyle Choice or Misuse of Prescription Drugs? Ethics Blind Spots in Current Debates. Neuroethics 3: 1-4.
20. Elliott C, (2000) Pursued by happiness and beaten senseless. Prozac and the American dream. Hastings Cent Rep 30: 7-12.
21. Juengst ET, (1998) What does Enhancement Mean? In: Parens E, editors. pp. 29-47 editor. Enhancing Human Traits: Ethical and Social Implications. Washington: Georgetown University Press.
22. Bramstedt KA, (2007) Caffeine use by children: the quest for enhancement. Subst Use Misuse 42: 1237-1251.
23. Caplan A, (2002) No-Brainer: Can We Cope with the Ethical Ramifications of New Knowledge of the Human Brain? In: Marcus SJ, editors. pp. 95-106 editor. Neuroethics: Mapping the Field. Chicago: University of Chicago Press.
24. Franke AG, Schwarze CE, Christmann M, Bonertz C, Hildt E, et al. (2012) [Characteristics of University Students Using Stimulants for Cognitive Enhancement: A Pilot Study.]. Psychiatr Prax In press.
25. Hildt E, Franke AG, Lieb K, (2011) [Pharmacological neuroenhancement: Information and acceptance among students] Nervenheilkunde 10: 833-837.
26. Corbin J, Strauss A, (2008) Basics of Qualitative Research: Techniques and Procedures for Developing Grounded Theory. Thousand Oaks: Sage Publications.
27. Mayring P, (2010) Qualitative Inhaltsanalyse: Grundlagen und Techniken. Landsberg: Beltz Verlag.
28. Bryant A, Charmaz K, (2010) The SAGE Handbook of Grounded Theory. London: Sage.
29. Ferre S, Ciruela F, Borycz J, Solinas M, Quarta D, et al. (2008) Adenosine A1-A2A receptor heteromers: new targets for caffeine in the brain. Front Biosci 13: 2391-2399.
30. Fisone G, Borgkvist A, Usiello A, (2004) Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci 61: 857-872.
31. Nehlig A, Daval JL, Debry G, (1992) Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain Res Brain Res Rev 17: 139-170.
32. Oades RD, Sadile AG, Sagvolden T, Viggiano D, Zuddas A, et al. (2005) The control of responsiveness in ADHD by catecholamines: evidence for dopaminergic, noradrenergic and interactive roles. Dev Sci 8: 122-131.
33. Prince J, (2008) Catecholamine dysfunction in attention-deficit/hyperactivity disorder: an update. J Clin Psychopharmacol 28: S39-45.
34. Wilens TE, (2008) Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 28: S46-53.
35. Killgore WD, Rupp TL, Grugle NL, Reichardt RM, Lipizzi EL, et al. (2008) Effects of dextroamphetamine, caffeine and modafinil on psychomotor vigilance test performance after 44 h of continuous wakefulness. J Sleep Res 17: 309-321.
36. Wesensten NJ, Killgore WD, Balkin TJ, (2005) Performance and alertness effects of caffeine, dextroamphetamine, and modafinil during sleep deprivation. J Sleep Res 14: 255-266.
37. Berman SM, Kuczenski R, McCracken JT, London ED, (2009) Potential adverse effects of amphetamine treatment on brain and behavior: a review. Mol Psychiatry 14: 123-142.
38. Caplan JP, Epstein LA, Quinn DK, Stevens JR, Stern TA, (2007) Neuropsychiatric effects of prescription drug abuse. Neuropsychol Rev 17: 363-380.
39. Hughes JR, Oliveto AH, Helzer JE, Higgins ST, Bickel WK, (1992) Should caffeine abuse, dependence, or withdrawal be added to DSM-IV and ICD-10? Am J Psychiatry 149: 33-40.
40. Satel S, (2006) Is caffeine addictive?-a review of the literature. Am J Drug Alcohol Abuse 32: 493-502.